Can a multiple myeloma drug shield the kidneys in MGRS?
NCT ID NCT04614558
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether isatuximab, an antibody drug already approved for multiple myeloma, can improve kidney function in people with monoclonal gammopathy of renal significance (MGRS). MGRS is a condition where abnormal proteins damage the kidneys. Participants receive isatuximab by IV for six months, and researchers measure whether protein in the urine drops by more than half, a sign of kidney improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isatuximab (Sarclisa), an antibody drug given by IV
- What this could lead to
- If it works, this could point toward a new treatment option to protect kidney function in people with MGRS.
- What could go wrong
- This is a small, early-phase trial with only 12 participants and no comparison group. Isatuximab is not yet approved for MGRS, and its effectiveness and safety for this condition are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Massachusetts General Hospital, Renal Associates Clinic
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.